<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-17-02-2026-shutterstock_2249605625-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-17-02-2026-shutterstock_2249605625-430x241.jpg"/></p>
<p>两家公司共同的目标是提供创新治疗方案，以改善患有妇科疾病女性的生活质量。图片来源：Peakstock / Shutterstock.com。</p>
<p>帝人制药与总部位于东京的 Aska Pharmaceutical 签署了联合研究协议，旨在开发针对妇科疾病的小分子药物候选物。</p>
<p>此次合作旨在加速早期药物发现，专注于创新疗法，利用帝人制药在计算机辅助药物设计（CADD）和人工智能方面的专业知识。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - GSK-4381562 在子宫内膜癌中的应用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - INCB-123667 在子宫内膜癌中的应用</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>根据协议，两家公司将专注于识别与特定分子靶点相互作用的 “命中” 化合物。</p>
<p>这些初步化合物将进一步优化，以确定潜在药物开发所需的有效性、药代动力学特性和安全性。</p>
<p>帝人制药通过提高模拟准确性和预测建模，推进其药物候选物发现过程，从而建立一个缩短时间线并提高药物开发成功概率的研究平台。</p>
<p>Aska Pharmaceutical 在满足现实临床需求方面积累了丰富经验，特别是在女性健康领域，并开发了一个专注于未满足医疗需求的产品组合。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>了解更多关于战略情报</p>
<p>该公司开发了广泛的产品，以支持女性在不同生命阶段的需求。</p>
<p>此次合作将结合帝人制药的先进药物发现技术与 Aska Pharmaceutical 在妇科疾病评估方面的临床专业知识。</p>
<p>两家公司共同的目标是提供创新治疗方案，以改善患有妇科疾病女性的生活质量。</p>
<p>Aska Pharmaceutical 专注于三个领域：泌尿科、内科（消化内科和甲状腺）以及妇产科。</p>
<p>帝人在全球范围内提供高性能材料和医疗解决方案，与合作伙伴共同提供符合其长期愿景的解决方案。</p>
<p>帝人最近向日本药品和医疗器械管理局提交了申请，寻求对 lonapegsomatropin（生长激素的前药）的生产和营销批准，该药物每周给药一次。</p>

3401

4886

<p>帝人制药与阿斯卡制药达成联合研究协议，共同开发用于妇科疾病的小分子药物候选物。此次合作旨在利用帝人公司在计算机辅助药物设计和人工智能方面的专业知识，加速早期药物发现。两家公司将专注于识别与特定分子靶点相互作用的化合物，并对其进行优化，以提高疗效和安全性。该合作伙伴关系旨在改善患有妇科疾病女性的生活质量，将帝人先进的药物发现技术与阿斯卡的临床专业知识相结合</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-17-02-2026-shutterstock_2249605625-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-2-17-02-2026-shutterstock_2249605625-430x241.jpg"/></p>
<p>Both companies share the goal of providing innovative treatments to improve quality of life for women with gynaecological conditions. Credit: Peakstock / Shutterstock.com.</p>
<div class="lb-trans"><p>两家公司共同的目标是提供创新治疗方案，以改善患有妇科疾病女性的生活质量。图片来源：Peakstock / Shutterstock.com。</p>
</div><p>Teijin Pharma has signed a joint research agreement with Tokyo-based Aska Pharmaceutical to develop small-molecule drug candidates for gynaecological diseases.</p>
<div class="lb-trans"><p>帝人制药与总部位于东京的 Aska Pharmaceutical 签署了联合研究协议，旨在开发针对妇科疾病的小分子药物候选物。</p>
</div><p>The collaboration aims to expedite early-stage drug discovery focused on innovative therapeutics, using Teijin Pharma’s expertise in computer-aided drug design (CADD) and AI.</p>
<div class="lb-trans"><p>此次合作旨在加速早期药物发现，专注于创新疗法，利用帝人制药在计算机辅助药物设计（CADD）和人工智能方面的专业知识。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - GSK-4381562 in Endometrial Cancer</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - GSK-4381562 在子宫内膜癌中的应用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - INCB-123667 in Endometrial Cancer</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - INCB-123667 在子宫内膜癌中的应用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Under the agreement, both companies will focus on identifying “hit” compounds that interact with specific molecular targets.</p>
<div class="lb-trans"><p>根据协议，两家公司将专注于识别与特定分子靶点相互作用的 “命中” 化合物。</p>
</div><p>These initial compounds will undergo further optimisation to establish the desired efficacy, pharmacokinetic properties, and safety required for potential drug development.</p>
<div class="lb-trans"><p>这些初步化合物将进一步优化，以确定潜在药物开发所需的有效性、药代动力学特性和安全性。</p>
</div><p>Teijin Pharma is advancing its drug candidate discovery process by enhancing simulation accuracy and predictive modelling, resulting in a research platform that shortens timelines and raises the probability of success in drug development.</p>
<div class="lb-trans"><p>帝人制药通过提高模拟准确性和预测建模，推进其药物候选物发现过程，从而建立一个缩短时间线并提高药物开发成功概率的研究平台。</p>
</div><p>Aska Pharmaceutical brings experience grounded in addressing real-world clinical needs, particularly in women’s health, and has developed a portfolio focused on unmet medical requirements in the field.</p>
<div class="lb-trans"><p>Aska Pharmaceutical 在满足现实临床需求方面积累了丰富经验，特别是在女性健康领域，并开发了一个专注于未满足医疗需求的产品组合。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>The company has developed a wide range of products to support women at various stages of life.</p>
<div class="lb-trans"><p>该公司开发了广泛的产品，以支持女性在不同生命阶段的需求。</p>
</div><p>The partnership will combine Teijin Pharma’s advanced drug discovery technologies with Aska Pharmaceutical’s clinical expertise in gynaecological disease evaluation.</p>
<div class="lb-trans"><p>此次合作将结合帝人制药的先进药物发现技术与 Aska Pharmaceutical 在妇科疾病评估方面的临床专业知识。</p>
</div><p>Both companies share the goal of providing innovative treatments to improve the quality of life for women with gynaecological conditions.</p>
<div class="lb-trans"><p>两家公司共同的目标是提供创新治疗方案，以改善患有妇科疾病女性的生活质量。</p>
</div><p>Aska Pharmaceutical specialises in three areas: urology, internal medicine (gastroenterology and thyroid), and obstetrics and gynaecology.</p>
<div class="lb-trans"><p>Aska Pharmaceutical 专注于三个领域：泌尿科、内科（消化内科和甲状腺）以及妇产科。</p>
</div><p>Teijin operates across high-performance materials and healthcare solutions worldwide, working with partners to deliver solutions aligned with its long-term vision.</p>
<div class="lb-trans"><p>帝人在全球范围内提供高性能材料和医疗解决方案，与合作伙伴共同提供符合其长期愿景的解决方案。</p>
</div><p>Teijin recently submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency seeking manufacturing and marketing approval for lonapegsomatropin, a prodrug of somatropin, which is administered once weekly.</p>
<div class="lb-trans"><p>帝人最近向日本药品和医疗器械管理局提交了申请，寻求对 lonapegsomatropin（生长激素的前药）的生产和营销批准，该药物每周给药一次。</p>
</div>

帝人公司与 Aska 制药公司将共同开发妇科药物